Clinical Trial

ASpirin Use and stAtin Strategy for Primary Prevention in Severe Coronary Calcium Score on Computed Tomography

Study acronym: ASA-3C
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The primary objective of the ASA-3C trial is to evaluate the role of aspirin and high-intensity statin therapy, respectively, in individuals with severe coronary calcification (coronary calcium score ≥300) to prevent atherosclerotic cardiovascular disease (ASCVD) events with severe coronary calcification (CAC ≥300).
Protocol Amendment History 2 changes
notable Trial sites expanded: 26 -> 32 locations 2026-07-02
notable Trial sites expanded: 1 -> 26 locations 2026-06-26
Trial Details
NCT Number NCT06676280
Lead Sponsor Jung-min Ahn
Conditions Cardiovascular Diseases
Enrollment 5,000 participants
Start Date 2025-07-24
Primary Completion 2035-03-31 (estimated)
Study Completion 2035-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-01